, Volume 93, Issue 3, pp 406-407
Date: 08 Mar 2011

Discrepancy in the kinetics of total and active anti-thymocyte globulin blood concentrations in recipients of allogeneic hematopoietic stem cell transplantation

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Anti-thymocyte globulin (ATG) has been used as a component of conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) primarily for graft rejection as well as graft-versus-host disease (GVHD) [1, 2]. Recently, ATG has been increasingly used as part of reduced-intensity conditioning (RIC), since ATG has a lower organ-toxicity profile than other anti-cancer agents [35]. However, the dose and timing of administration of ATG varies significantly among the studies; thus, its optimal treatment schedule has yet to be elucidated. Furthermore, there are only a limited number of reports evaluating the pharmacokinetics of ATG in the setting of conditioning for allogeneic HSCT [68], which we think is very important to elucidate this issue. Theoretically, the higher the blood concentration of ATG at the time of transplantation, the lower the incidence and severity of GVHD should be. Remberger et al. [7, 8] have shown a significant relationship between blood concentration of ATG